Takeda San Diego
Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases and cancer. Multiple drug candidates discovered at TSD are currently in clinical trials including SYR322, a potential treatment for type II diabetes.
Management Team
Keith P. Wilson, Ph.D. - President and Chief Scientific Officer
David J. Weitz, J.D. - Senior Vice President, U.S. Intellectual Property Department and General Counsel
Jeffrey A. Stafford, Ph.D. - Vice President of Chemistry
Umi Chong - Senior Director, Finance
Ronald J. Christopher, Ph.D., D.A.B.T. - Senior Director, Development
Kenneth E. Goodwill, Ph.D. - Senior Director of Alliance Management
Daniel B. Kassel, Ph.D. - Senior Director, Analytical and Discovery Technologies
A. Robert MacLeod, Ph.D. - Senior Director, Discovery Biology
David M. Stemerick, J.D. – Senior Corporate Counsel, Takeda San Diego Intellectual Property
Takeda Pharmaceutical Company Limited
Takeda was founded in 1781, and recorded over $10B in sales in 2004. Takeda markets a number of blockbuster drugs discovered through its internal research programs including Actos ® (diabetes), Blopress ® (cardiovascular disease), and Prevacid ® (ulcer). Takeda has more than 2000 US-based employees and is rapidly growing its US operations.